Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274794 · ClinicalTrials.gov registry record · NA
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT00274794 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 55 participants.
The verdict
NCT00274794, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, or chemotherapy, such as etoposide, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant. Giving etoposide and G-CSF together with rituximab before a peripheral stem cell transplant may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This randomized clinical trial is studying how well giving etoposide and G-CSF with or without rituximab works in treating patients who are undergoing an autologous peripheral stem cell transplant for B-cell non-Hodgkin's lymphoma.
Interventions
- BIOLOGICAL rituximab
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2000-02 |
| Est. Completion | 2006-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274794
The ClinicalTrials.gov registry entry for NCT00274794 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00274794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274794 about?
NCT00274794 is a clinical study titled "VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL". RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituxim...
What is the current status of trial NCT00274794?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2000-02. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00274794?
The interventions under investigation include: rituximab (BIOLOGICAL), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00274794?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.